market turmoil impacts ipos

Wall Street’s billion-dollar IPO dreams got crushed when Trump’s tariff bombshell sent markets into a tailspin. Heavy hitters Klarna and StubHub quickly abandoned ship, shelving their public offerings amid the chaos. The buy-now-pay-later sector took a particularly nasty hit, with Affirm’s stock nosediving 30% in just two days. Recent IPO flops like U Power’s 97% plunge paint a grim picture of what’s lurking beneath these turbulent waters.

market turmoil affects ipos

While Wall Street hoped for a resurgence in billion-dollar IPOs this year, those dreams are getting crushed. Trump’s latest tariff announcements sent markets into a tailspin, with tech darlings like Tesla and Nvidia leading the downward spiral. The chaos has forced major players to hit the brakes on their IPO plans. Thorough due diligence reviews by underwriters have highlighted the risks of launching in this volatile environment.

Klarna, the buy-now-pay-later giant, just shelved its planned New York Stock Exchange debut. So much for that $15 billion valuation target. The Swedish fintech company, which pulled in $2.81 billion in revenue last year, decided market instability wasn’t worth the risk. Smart move, considering how Affirm’s stock just nosedived 30% in two days – its second-worst week ever. Most trading activity occurs in the secondary market where existing shares change hands.

Klarna’s NYSE retreat signals trouble ahead, as market turmoil sends buy-now-pay-later stocks into freefall despite robust revenue growth.

StubHub joined the retreat parade, pausing its plans to raise over $1 billion in early April. Turns out, trying to convince investors to bet on ticketing platforms during market turbulence is about as fun as trying to sell ice cream in a snowstorm. The dramatic 85% drop from 2021 in U.S. IPO listings shows just how severe the market downturn has become.

The track record for recent IPOs isn’t exactly inspiring confidence. Just look at U Power, down a jaw-dropping 97%. Energy, healthcare, and media sectors? Total bloodbath. Companies like Lucy Scientific Discovery and Mangoceuticals have become cautionary tales of what not to do in this market.

History’s greatest IPO flops are getting some new company. Remember Uber’s 2019 fumble when it missed that ambitious $120 billion valuation target? Or SmileDirectClub’s 27.5% first-day face plant? Today’s market is serving up fresh failures with ruthless efficiency.

The buy-now-pay-later sector is feeling particularly vulnerable. Affirm’s market value has shrunk to $11 billion, while rising consumer credit risks have investors sweating bullets. With Trump’s tariffs threatening to jack up prices across the board, the timing couldn’t be worse for companies banking on Americans’ willingness to take on more debt.

The IPO market’s attempted comeback is looking more like a false start. For now, those billion-dollar dreams will have to wait.

You May Also Like

Trump’s Auto Tariffs Could Devastate U.S. Car Market Like COVID or 2008 Crash, Say S&P Analysts

Trump’s auto tariffs could force Americans to pay $10,000 more for vehicles, potentially wreaking havoc worse than the 2008 financial crisis. The industry hangs by a thread.

Inside China’s High-Stakes Battle to Outsmart Crushing U.S. Tariffs

China’s trade war arsenal is deadlier than ever: rare earth minerals and 125% tariffs spell trouble for U.S. markets and supply chains.

Why Novo Nordisk (NVO) Might Be Wall Street’s Most Underrated Biotech Powerhouse

Novo Nordisk is the biotech world’s quiet giant, quietly dominating diabetes and obesity care. Why is Wall Street overlooking this powerhouse? The shocking truth is waiting to be revealed.

Tariffs Slam Markets in 2025—But Analysts Say the Real Economic Pain Is Just Beginning

Devastating tariffs crush markets and rob families of thousands – but experts say the real economic nightmare hasn’t even started.